Melanoma accounts for a small fraction of all skin cancers but causes the large majority of skin-cancer deaths, because it can spread to distant organs if not caught early. It arises from melanocytes, the pigment-producing cells in your skin, and typically shows up as a new or changing mole with irregular color, shape, or borders. The good news is that early-stage melanoma is highly curable with surgery alone, and recent advances in immunotherapy and targeted drugs have transformed outcomes even for advanced disease.
Recognizing the Warning Signs
The most widely taught method for spotting a suspicious mole is the ABCDE checklist, which became a public education staple in the mid-1980s and has been refined since then.1PubMed Central. Evolution of the Clinical, Dermoscopic and Pathologic Diagnosis of Melanoma The letters stand for Asymmetry (one half doesn’t mirror the other), Border irregularity (edges are ragged or blurred), Color variation (multiple shades of brown, black, red, white, or blue within the same lesion), Diameter (larger than about 6 mm, roughly the size of a pencil eraser), and Evolving (any change in size, shape, or color over time). Not every melanoma checks all five boxes, but any one feature, especially evolution, warrants a closer look.
A second, less well-known approach is the “ugly duckling” sign. Instead of scrutinizing a mole against a checklist, you compare it against the rest of your moles. If one lesion looks obviously different from its neighbors, it deserves attention. A study that tested this approach found that people trained to look for ugly ducklings were significantly more accurate at distinguishing melanoma from harmless moles, with higher specificity than those using the ABCDE criteria alone.2PubMed. The role of the ugly duckling sign in patient education Both methods work best together: the ABCDE criteria tell you what to look for in a single mole, while the ugly duckling sign helps you decide which mole to worry about in the first place.
The Main Types of Melanoma
Melanomas are grouped into histological subtypes based on how they grow and where they appear. The two most common are superficial spreading melanoma and nodular melanoma. For decades, dermatologists assumed these were stages of the same process: melanoma cells first spread outward along the skin surface (the radial growth phase) and then eventually punch downward into deeper tissue (the vertical growth phase). More recent clinical and molecular evidence challenges that assumption, suggesting that superficial spreading and nodular melanomas may actually be biologically distinct entities rather than sequential steps on one path.3PubMed Central. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model
Superficial spreading melanoma is the most common subtype overall. It tends to grow outward along the skin for a period before invading deeper layers. Research using machine learning to analyze hundreds of cases found that for non-nevus-associated superficial spreading melanomas, the transition from radial to vertical growth tended to occur at a tumor diameter around 13 mm.4PubMed. Machine learning for the identification of decision boundaries during the transition from radial to vertical growth phase superficial spreading melanomas That doesn’t mean every melanoma below that size is safe, but it underscores why early detection matters: catching a superficial spreading melanoma while it’s still thin and flat gives you the best chance of a cure.
Nodular melanoma, by contrast, tends to grow vertically from the start. It often appears as a raised, dome-shaped bump that may be uniformly dark or even flesh-colored. Because it skips the long radial-growth phase, it can reach dangerous thickness quickly, which makes it disproportionately responsible for melanoma deaths relative to how common it is.
Acral Lentiginous Melanoma
Acral lentiginous melanoma (ALM) develops on the palms, soles, and under the nails, areas that get relatively little sun exposure.5PubMed Central. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease It is the most common melanoma subtype in people with darker skin tones, although it occurs in all racial groups. In a study of acral melanomas in Caucasian patients, the five-year survival rate for those without detectable spread at diagnosis was about 82%, and ALM carried a significantly worse prognosis than superficial spreading melanoma at the same site.6British Journal of Dermatology. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients Part of the survival gap traces to later diagnosis: a dark streak under a toenail or a discolored patch on the sole is easy to dismiss or miss entirely.
Uveal Melanoma
Melanoma doesn’t only happen on the skin. Uveal melanoma arises inside the eye, and it behaves very differently from cutaneous melanoma. Its genetic drivers are distinct, centering on mutations in genes called GNAQ and GNA11 rather than the BRAF and NRAS mutations common in skin melanomas. Despite good local control with radiation or surgery, up to half of uveal melanoma patients eventually develop metastases, and the targeted therapies and immunotherapies that have transformed outcomes for skin melanoma have been largely disappointing for the uveal form.7PubMed. Development of new therapeutic options for the treatment of uveal melanoma
The Sun Exposure Paradox
Everyone knows that ultraviolet radiation increases melanoma risk, but the relationship is more nuanced than “more sun equals more cancer.” A large meta-analysis found that intermittent sun exposure, the kind you get during vacations, weekend sports, or occasional sunbathing, and a history of sunburn were strongly associated with melanoma risk. High occupational sun exposure, on the other hand, was inversely associated with melanoma, meaning people who worked outdoors regularly were actually at lower risk.8PubMed. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure Older northern-hemisphere studies showed the same pattern: recreational and vacation sun exposure was linked to higher melanoma rates, while regular outdoor occupation conferred a decreased risk.9PubMed. Melanoma and sun exposure: contrasts between intermittent and chronic exposure
The hypothesis is that brief, intense bursts of UV overwhelm skin cells that aren’t adapted to handle that level of exposure, causing the kind of DNA damage that tips melanocytes toward malignancy. Chronic, steady exposure may allow the skin’s protective mechanisms, like tanning and DNA-repair pathways, to keep pace. Some more recent studies have complicated this picture by suggesting that in certain populations, intermittent childhood exposure might even be protective, so the intermittent-exposure hypothesis isn’t universally accepted.10PubMed Central. Sun exposure and risk of melanoma Still, the practical takeaway stands: avoiding sunburns matters more than avoiding all sun.
On the prevention front, the strongest direct evidence comes from a randomized trial in Australia. People assigned to use sunscreen daily had roughly half the rate of new melanomas over long-term follow-up compared to those who used sunscreen at their own discretion, and the reduction was especially striking for invasive melanomas.11PubMed. Reduced melanoma after regular sunscreen use: randomized trial follow-up
Key Genetic Mutations and Why They Matter for Treatment
About half of cutaneous melanomas harbor a mutation in the BRAF gene, most commonly a single change at a specific spot called V600E. This mutation locks a cell-growth signaling pathway into the “on” position, driving uncontrolled proliferation.12PubMed Central. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers Knowing whether your melanoma carries a BRAF mutation is critical because it determines whether you’re eligible for targeted therapy (more on that below).
Another subset of melanomas carries NRAS mutations instead. NRAS-mutant melanoma tends to be more aggressive and associated with poorer outcomes than non-NRAS-mutant disease.13PubMed Central. Targeting mutant NRAS signaling pathways in melanoma There’s currently no FDA-approved targeted therapy specifically for NRAS-mutant melanoma, so these patients typically rely on immunotherapy.
Diagnosis and Staging
When a mole looks suspicious, the next step is a biopsy. The pathologist measures the tumor’s thickness in millimeters, a measurement called the Breslow thickness. This is the single most important number in early melanoma. Tumors are categorized as thin (under 1 mm), intermediate (1 to 4 mm), or thick (over 4 mm), and that thickness drives treatment decisions, prognosis, and survival estimates.14PubMed Central. Diagnostic biopsy of cutaneous melanoma, sentinel lymph node biopsy and indications for lymphadenectomy
For melanomas thicker than about 1 mm, guidelines recommend a sentinel lymph node biopsy, a procedure that checks whether cancer cells have reached the nearest lymph nodes. For very thin, non-ulcerated melanomas (under 0.8 mm), a sentinel node biopsy is generally not recommended because the risk of spread is low. Between 0.8 and 1 mm, or if ulceration is present, the decision is made on a case-by-case basis after discussing the pros and cons with the patient.15PubMed. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update At least one study has questioned whether sentinel node status adds independent prognostic information beyond what Breslow thickness already tells you, so this remains an evolving area of debate.16Journal of the American Academy of Dermatology. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma
Advanced Imaging Tools
Beyond the standard biopsy, a technology called reflectance confocal microscopy (RCM) lets clinicians examine skin at near-cellular resolution without cutting. A Cochrane systematic review found RCM was substantially more accurate than standard dermoscopy, especially for hard-to-diagnose lesions. At a fixed sensitivity of 90%, RCM had a specificity of 82% compared with 42% for dermoscopy, translating to far fewer unnecessary excisions.17PubMed Central. Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults RCM isn’t available everywhere, but it’s becoming a valuable second-line tool at specialized dermatology centers, particularly for equivocal lesions where a clinician isn’t sure whether to cut or watch.
Surgical Treatment
Surgery is the primary treatment for melanoma confined to the skin. After the initial biopsy, a wider excision removes additional tissue around the original site to reduce the chance of recurrence. How wide depends on the tumor’s thickness: melanoma in situ (confined to the top layer of skin) needs margins of 5 to 10 mm, while invasive melanomas up to 1 mm thick need 1 cm margins, and thicker tumors need 1 to 2 cm margins.18PubMed. Updated evidence-based clinical practice guidelines for the diagnosis and management of melanoma: definitive excision margins for primary cutaneous melanoma
You might wonder why margins aren’t simply made as wide as possible. A systematic review and meta-analysis comparing wide excision (3 to 5 cm margins) to narrower excision (1 to 2 cm) found no significant differences in overall survival, disease-free survival, or local recurrence.19PubMed Central. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis Wider cuts mean larger scars, more complex wound closures, and sometimes skin grafts, all for no measurable survival benefit. The current guidelines reflect decades of trials finding that 1 to 2 cm is enough.
Immunotherapy
Immunotherapy has been the biggest shift in melanoma treatment over the past decade. Immune checkpoint inhibitors work by releasing the brakes that cancer cells put on your immune system. Two main classes target different checkpoints: anti-PD-1 drugs (like nivolumab and pembrolizumab) and anti-CTLA-4 drugs (like ipilimumab). A meta-analysis comparing checkpoint inhibitors to chemotherapy in advanced melanoma found that checkpoint inhibitors improved one-year survival from about 39% to 51%, and anti-PD-1 agents outperformed anti-CTLA-4 drugs on both progression-free survival and response rates.20PubMed Central. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
Combining both types of checkpoint inhibitors can improve outcomes further, but it also increases side effects. A real-world study found that combination therapy was associated with better survival in patients whose melanoma had spread to more than two organ systems, but actually fared worse in patients with limited spread. Patients with limited-spread disease who received the combination were also hospitalized for immune-related side effects at much higher rates (about 31% versus 9%).21BJC Reports. Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study The implication is that the most aggressive treatment isn’t always the best choice; it depends on how widely the cancer has spread.
Targeted Therapy for BRAF-Mutant Melanoma
If your melanoma tests positive for a BRAF V600 mutation, you may be treated with a combination of two drugs that block the overactive growth-signaling pathway. Three FDA-approved pairings exist: dabrafenib with trametinib, vemurafenib with cobimetinib, and encorafenib with binimetinib.22PubMed Central. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma These combinations can produce rapid, dramatic tumor shrinkage. The trade-off is that resistance typically develops after about a year in most patients.23PubMed. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Research into how resistance arises has identified several mechanisms. In one study of tumors that progressed on combined dabrafenib and trametinib, the growth-signaling pathway had reactivated in the vast majority of cases, through routes including extra copies of the BRAF gene itself, new mutations in the MEK genes, and new NRAS mutations.24Nature Communications. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma Understanding these escape routes is guiding the development of next-line treatments and combination strategies designed to block them.
Emerging Treatments
Two newer therapeutic approaches are generating particular excitement. The first is tumor-infiltrating lymphocyte (TIL) therapy, which involves extracting immune cells from a patient’s tumor, growing them to large numbers in the lab, and infusing them back. Lifileucel became the first FDA-approved TIL therapy for advanced melanoma, and five-year follow-up of the pivotal trial showed an objective response rate of about 31% in heavily pretreated patients, with some responses lasting years.25PubMed Central. Top advances of the year in autologous cellular therapy in melanoma and solid tumors That response rate may sound modest, but this is a population where most standard therapies have already failed.
The second frontier is personalized cancer vaccines. Rather than off-the-shelf vaccines, these are custom-built for each patient based on the unique mutations in their tumor. The technology relies on rapid genetic sequencing of the tumor followed by mRNA or peptide-based delivery, a platform accelerated in part by advances from COVID-19 vaccine development. Early trials in melanoma have shown immune activation and improved recurrence-free survival, although large confirmatory studies are still underway.26PubMed. Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View
After Treatment: Recurrence and Surveillance
Even after successful treatment, melanoma can return. In a study of patients with stage II melanoma (meaning the primary tumor was relatively thick but had no detected spread to lymph nodes or distant sites), about 27% experienced a recurrence over a median follow-up of nearly five years. Most of those recurrences were discovered by the patients themselves, not by imaging. However, routine imaging scans were significantly more likely to catch distant recurrences and recurrences in people with the highest-risk stage II disease.27PubMed. Recurrence patterns in patients with Stage II melanoma: The evolving role of routine imaging for surveillance Men were also less likely to self-detect recurrences than women, which is one reason some clinicians advocate more aggressive surveillance schedules for male patients.
Disparities in Who Gets Diagnosed and How They Fare
Melanoma is most common in fair-skinned populations, but when it occurs in people with darker skin, it tends to be diagnosed later and carries worse outcomes. Acral lentiginous melanoma disproportionately affects Black and Hispanic patients, and a study of ALM outcomes found that Hispanic White and Black patients had roughly 1.5 and 1.25 times the risk of death, respectively, compared to non-Hispanic White patients. Much of that gap shrank after adjusting for socioeconomic status and stage at diagnosis, suggesting that delayed access to care and later-stage presentation drive the disparity more than any biological difference.28Journal of the American Academy of Dermatology. Socioeconomic status and race are associated with survival in acral lentiginous melanoma
Geography plays a role too. In Texas, residents of nonmetropolitan areas were roughly 39% more likely to be diagnosed with melanoma than those in metropolitan areas, and poverty rates further stratified the risk within rural communities.29PubMed Central. Comparison of melanoma incidence in metropolitan areas versus nonmetropolitan areas in the state of Texas stratified by poverty classification Higher rates of outdoor work and fewer dermatologists per capita in rural areas are likely contributors.
Melanoma in Children and Adolescents
Pediatric melanoma is rare but carries unique challenges. Three main subtypes are recognized in children: Spitzoid melanoma, melanoma arising in a congenital mole, and conventional (adult-type) melanoma. Spitzoid melanomas frequently involve sentinel lymph nodes yet often follow a surprisingly benign clinical course. Melanoma arising in large congenital nevi, by contrast, tends to be aggressive and accounts for most melanoma-related deaths in childhood.30The Lancet Child & Adolescent Health. Paediatric melanoma: a review Children also more often present with amelanotic (non-pigmented) lesions, which look nothing like the dark, irregular moles described in adult screening campaigns, leading to frequent delays in diagnosis.31PubMed Central. Diagnostic and Therapeutic Challenges in Pediatric Cutaneous Melanoma: Two Case Reports From the Moroccan Population
Artificial Intelligence in Melanoma Screening
AI-powered image analysis tools have drawn attention for their ability to classify skin lesions from photographs. A large meta-analysis found that AI was reported as non-inferior or superior to dermatologists in the vast majority of head-to-head comparisons, with pooled sensitivity around 86% and specificity around 94% for melanoma diagnosis.32PubMed Central. Diagnostic accuracy of artificial intelligence compared to family physicians and dermatologists for skin conditions: a systematic review and meta-analysis Those numbers look impressive, but the studies have serious caveats. Most AI models were trained on the same few image datasets, which over-represent lighter skin tones and high-quality dermatoscopic images. They also lack the clinical context a real dermatologist uses, such as patient history, how a lesion feels on palpation, and whether it has changed over time.33npj Digital Medicine. A systematic review and meta-analysis of artificial intelligence versus clinicians for skin cancer diagnosis In practice, AI tools are best understood as decision-support aids rather than standalone diagnosticians, useful for flagging lesions that deserve a closer look but not ready to replace a trained clinician’s judgment.
The Psychological Toll of a Melanoma Diagnosis
Even when melanoma is caught early and cured, the diagnosis leaves a mark. A population-based study found that anxiety and depressive symptoms were significantly more common in melanoma survivors than in the general population, with about 31% of survivors reporting these issues compared to about 22% in matched controls. Fear of recurrence was the most prevalent concern, reported by nearly half of survivors, and roughly one in five had unmet needs for psychological support.34PubMed. Patient-reported outcomes in melanoma survivors at 1, 3 and 5 years post-diagnosis: a population-based cross-sectional study A qualitative study of survivors with localized melanoma, including some with stage 0 disease, found that the majority scored above the clinical threshold for fear of cancer recurrence, with many describing intense emotions around follow-up appointments and lasting changes in how they relate to sun exposure, their bodies, and mortality.35PubMed Central. Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma Dispositional pessimism, self-blame, and negative social interactions were all associated with worse psychological outcomes in long-term survivors.36PLoS ONE. Depression, Anxiety and Quality of Life in Long-Term Survivors of Malignant Melanoma: A Register-Based Cohort Study If you’ve been treated for melanoma and find yourself fixating on the possibility of recurrence, that reaction is not unusual and is worth raising with your care team.